Navigation Links
Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board

RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in the development of new proprietary fluorescent metal-lanthanide technology for use in high-value applications, announced that it has signed an exclusive agreement with Biophor Diagnostics, Inc., Redwood City, California to apply Lumiphore products in diagnostic tests for drugs of abuse.

Under the agreement, Biophor Diagnostics holds the exclusive worldwide rights to Lumi4(TM) technology in current and future diagnostic tests of this type. Lumi4(TM) fluorescent metal-reporter compounds bring increased sensitivity, stability, and robustness to assays in the drugs of abuse testing market through their excellent fade-resistant photophysical properties.

This is the third strategic partnership reached by Lumiphore in the past three years. Previous partnerships include Cis Bio International ( for the drug discovery research market and Echelon Biosciences Inc. ( for novel cancer assays involving phospholipid signaling and lipid-protein interactions.

The company today also announced the appointment of Dr. David J. Ecker to its board of directors. Dr. Ecker is Chief Scientific Officer and a founder of Ibis Biosciences and a co-founder and Vice President of Isis Pharmaceuticals. He brings to the board deep experience in successful biotech commercialization as well as specific technical expertise in detection and assay platforms.

Dr. Ecker has over 24 years of experience in the pharmaceutical/biotechnology industry in cancer and infectious disease research and development. He was a primary inventor of the Ibis T5000 biosensor technology, and has authored more than 80 scientific publications and over 50 U.S. patents. His extensive publications span biosensor technology, infectious disease research, biodefense and gene construction/expression. His previous experience includes assistant director, Department of Molecular Genetics at SmithKline and French (now GlaxoSmithKline).

About Lumiphore | Based in Richmond, California, Lumiphore is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications which are commercialized through market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. Metal lanthanide reporters provide increased sensitivity for fluorescent reagents in biology through time-resolved detection which vastly improves assay signals over background noise. For more information about Lumiphore, log onto

Lumi4(TM) is a trademark of Lumiphore, Inc.

CONTACT: Stephen Blose, +1-415-381-4457, for Lumiphore, Inc.

SOURCE Lumiphore, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
2. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
4. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
5. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
7. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
8. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
9. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
10. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
11. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
Post Your Comments:
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015  Vigilant Solutions announces today that Mr. ... of Directors. --> --> ... from the partnership at TPG Capital, one of the ... $140 Billion in revenue.  He founded and led TPG,s ... TPG companies, from 1997 to 2013.  In his first ...
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
Breaking Biology News(10 mins):